Holen Sie sich die Stockscreener-App
0.3282
2.56%
0.0082
Handel nachbörslich:
.33
0.0018
+0.55%
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Issues Positive Forecast for ACXP Earnings - Defense World
FY2029 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress - TipRanks
Earnings call transcript: Acurx Pharmaceuticals Q4 2024 sees narrower EPS loss - Investing.com Canada
ACXP stock touches 52-week low at $0.43 amid market challenges - Investing.com UK
Acurx Pharmaceuticals, Inc Full Year Loss Narrows - Nasdaq
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Yahoo Finance
Earnings Scheduled For March 18, 2025 - Benzinga
Acurx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP - Milton Daily Standard
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Announces Closing of $1.1 Million Registered Direct Offering -March 10, 2025 at 05:37 pm EDT - MarketScreener
ACXPAcurx Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Dow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results - Benzinga
Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30% - Benzinga
Acurx Pharmaceuticals Launches $1.1 Million Registered Direct Offering; Shares Fall -March 07, 2025 at 10:07 am EST - Marketscreener.com
Nasdaq Gains 100 Points; US Economy Adds Fewer Jobs Than Projected - Benzinga
Acurx Pharmaceuticals stock sinks on $1.1M direct offering - MSN
Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering -March 07, 2025 at 08:14 am EST - Marketscreener.com
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decrease in Short Interest - Defense World
ACXP stock touches 52-week low at $0.66 amid market challenges - Investing.com
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Yahoo Finance
Can Acurx's Antibiotic Revolutionize C. Difficile Treatment? New Microbiome Data Suggests Yes - Stock Titan
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update - Yahoo Finance
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Acurx's ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com South Africa
Acurx's ibezapolstat shows selective bacterial targeting - Investing.com India
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI - Longview News-Journal
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative… - Informazione.it
ACXP stock touches 52-week low at $0.67 amid market challenges - Investing.com UK
Acurx Pharmaceuticals secures Japanese patent for antibiotics By Investing.com - Investing.com South Africa
Acurx Pharmaceuticals secures Japanese patent for antibiotics - Investing.com India
Dual Victory for Acurx: Japanese Patent Grant Follows EMA's Green Light for Phase 3 Antibiotic Trial - StockTitan
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming - StreetInsider.com
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Drops By 52.2% - Defense World
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):